Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes (Q45117146)

9 December 2017

title

Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes (English)

1 reference

9 December 2017

1 reference

1 reference

1

Norio Yasui-Furukori

1 reference

9 December 2017

Masato Saito

2

1 reference

9 December 2017

Tsukasa Uno

3

1 reference

9 December 2017

Takenori Takahata

4

1 reference

9 December 2017

Kazunobu Sugawara

5

1 reference

9 December 2017

Tomonori Tateishi

6

1 reference

9 December 2017

publication date

1 November 2004

1 reference

The Journal of Clinical Pharmacology

9 December 2017

published in

1 reference

9 December 2017

volume

44

1 reference

9 December 2017

issue

11

1 reference

9 December 2017

page(s)

1223-1229

1 reference

Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders

9 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Genetic polymorphism of S-mephenytoin hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Pharmacokinetics of selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Clinically significant drug interactions with antidepressants in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Fluvoxamine interaction with warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

Inhibition of P-glycoprotein by newer antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270004269015

21 January 2018

Identifiers

DOI

10.1177/0091270004269015

1 reference

9 December 2017

1 reference